PremiumThe FlySandoz shareholders approve all resolutions at Annual General Meeting Sandoz Files Antitrust Lawsuit Against Amgen Over Biosimilar Blockade Sandoz files antitrust litigation against Amgen regarding Enbrel PremiumThe FlySandoz price target raised to CHF 44 from CHF 42 at RBC Capital Sandoz upgraded to Buy from Hold at Deutsche Bank Sandoz price target lowered to CHF 38 from CHF 41 at Morgan Stanley